INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.02
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.39

02 May
2025

-0.010

OPEN

$2.40

-0.42%

HIGH

$2.41

3,003,337

LOW

$2.33

TARGET
$3.123 30.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 26.0 8.5 xxx
DPS (cps) xxx 5.8 6.2 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 3.3% 6.0% xxx
PE Ratio xxx N/A 28.3 xxx
Dividend Yield xxx N/A 2.6% xxx
Div Pay Ratio(%) xxx N/A 72.6% xxx

Dividend yield today if purchased 3 years ago: 1.51%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.42

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-26.0
DPS All xxxxxxxxxxxxxxx5.8
Sales/Revenue xxxxxxxxxxxxxxx469.7 M
Book Value Per Share xxxxxxxxxxxxxxx129.0
Net Operating Cash Flow xxxxxxxxxxxxxxx66.2 M
Net Profit Margin xxxxxxxxxxxxxxx-12.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-17.99 %
Return on Invested Capital xxxxxxxxxxxxxxx-8.89 %
Return on Assets xxxxxxxxxxxxxxx-7.67 %
Return on Equity xxxxxxxxxxxxxxx-17.99 %
Return on Total Capital xxxxxxxxxxxxxxx6.00 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx28.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx16 M
Long Term Debt xxxxxxxxxxxxxxx342 M
Total Debt xxxxxxxxxxxxxxx358 M
Goodwill - Gross xxxxxxxxxxxxxxx373 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx42 M
Price To Book Value xxxxxxxxxxxxxxx2.07

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx23.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.08 %
Cost of Goods Sold xxxxxxxxxxxxxxx366 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx62 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/02/2025

1

Buy

$3.00

25.52%

Integral Diagnostics reported 1H results weaker-than-expected by Ord Minnett, with adjusted earnings (EBITDA) of $47m, missing forecast by around -8%.

Revenue growth of 8.4% in Australia and 6.6% in New Zealand also fell below the broker's expectations, and costs increased, particularly staff costs.

Despite these challenges, the broker remains optimistic, expecting improvements in FY26, driven by Capitol Health synergies, MRI deregulation from July 2025, and national lung cancer screening funding.

Regulatory tailwinds, including the proposed bulk-billing expansions, should also support long-term growth, suggest the analysts.

The broker lowers its FY26-28 EPS by -17%-21% and the target falls to $3.00 from $3.30. The rating is maintained at Buy.

FORECAST
Ord Minnett forecasts a full year FY25 dividend of 6.40 cents and EPS of 6.60 cents.
Ord Minnett forecasts a full year FY26 dividend of 9.00 cents and EPS of 13.00 cents.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

05/03/2025

1

Overweight

$2.75

15.06%

Integral Diagnostics's 1H25 result disappointed Wilsons with revenue missing forecasts and operating margins of 9.6% falling short by -86bps mainly due to higher costs, including from clinical staff shortages.

Still, the broker remains optimistic ahead of the integration with Capitol Health and continues to value the merged entity at 10x EV/EBITDA.

The broker made modest changes to standalone revenue and operating margins and also moderated Capitol Health margins to capture slower benefit of synergies.

Target price is $2.75. Overweight rating stays.

FORECAST
Wilsons forecasts a full year FY25 dividend of 6.00 cents and EPS of 7.30 cents.
Wilsons forecasts a full year FY26 dividend of 8.00 cents and EPS of 11.20 cents.

Canaccord Genuity

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
Australian Broker Call *Extra* Edition – May 05, 2025

10:35 AM - Daily Market Reports
2
Rudi’s View: Best Buys & Conviction Calls On ASX

Apr 10 2025 - Rudi's View
3
Rudi’s View: Best Buys In Copper, Small Caps, Tech, Healthcare, And More

Mar 20 2025 - Rudi's View
4
ESG Focus: Fund Flows, Tariffs, Defence & AI

Mar 20 2025 - ESG Focus
5
February Result Season 2025: The Wrap

Mar 14 2025 - Feature Stories

Latest Medical Equipment & Devices News

1
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
2
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
3
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
4
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
5
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
6
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
7
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
8
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
9
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
10
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals